Sitryx Therapeutics is taking groundbreaking steps in disease modification by targeting the metabolism of immune cells. Co-founded in 2018 and based in Oxford, the biopharmaceutical firm is developing first-in-class immuno-oncology and immuno-inflammation therapies that regulate cell metabolism. With seed funding from SV Health Investors, the company raised $30 million in series A funding from an international syndicate of specialist investors, including Sofinnova Partners, Longwood Fund, and GSK. Here’s a closer look at Sitryx Therapeutics, the uses of immunometabolism, and the future of the biotechnology industry in the UK.
Collaboration from world-leading scientists
The Sitryx Therapeutics team includes some of the brightest minds in the field with decades of experience in academia and industry. Dr. Houman Ashrafian (our co-founder and CEO), Professor Luke O’Neill, Dr. James Nathan, and Professor Jeff Pollard (our scientific advisory board member) have published hundreds of peer-reviewed papers, and they are each members of the world’s leading scientific societies. Together, they aim to leverage their knowledge of immunometabolism to create effective and safe therapies for severe diseases.
Unlocking the potential of immunometabolism
Immunometabolism is a fast-evolving scientific discipline that examines how nutrients and oxygen impact the immune cells necessary for the immune system’s proper function. Sitryx Therapeutics is at the forefront of innovation in this area, aiming to develop therapies that improve immune cells’ metabolic functions. By modulating cells’ metabolisms, the company seeks to improve immunotherapy’s efficacy by targeting aspects of cells that current treatments don’t address.
Advancing medical treatments with Sitryx’s pipeline
Sitryx’s pipeline targets a variety of debilitating diseases. With a diverse array of therapeutic approaches, the company is positioned to develop therapies specific to each condition. Among the patients’ clinical needs that Sitryx is addressing are cancer, autoimmune diseases, inflammation, and fibrosis. Several promising pre-clinical and clinical trials are underway to explore the company’s innovative therapies’ potential. If successful, Sitryx’s ingenious drug discovery and invention will change the future of medicine.
Future of the biotech industry in the UK
Sitryx Therapeutics is just one example of the UK’s burgeoning biotech industry, which is experiencing impressive growth. Groundbreaking companies like Sitryx, who focus on developing innovative therapies that address longstanding medical issues, have a significant impact on the future of medicine. With the support of leading venture capitalists and government-backed initiatives, the biotech industry is quickly becoming a vital contributor to the UK economy. It is expected to hit a £700 billion valuation globally by 2025. The UK is well-positioned to continue growing its world-renowned biotech firms and maintaining its competitive edge on the global stage.
Conclusion
Sitryx Therapeutics is an excellent example of a British firm that turns cutting-edge medical research into successful and effective solutions for global health issues. By strategically targeting immune cells’ metabolism, the company aims to develop a new class of groundbreaking immuno-oncology and immuno-inflammation therapies that will benefit millions. It’s an exciting time for the biotech industry in the UK, and Sitryx Therapeutics is positioned to be at the vanguard of this growing field.
Website: http://www.sitryx.com
Twitter: https://twitter.com/SitryxTher
Facebook: https://www.facebook.com/SitryxTher/
LinkedIn: https://www.linkedin.com/company/sitryxtherapeuticslimited/
Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.
